In line with these findings, the resistance-mediating effect of FB2-CM addition to lorlatinib-treated H2228 and H3122 tumor spheroids was partially inhibited by neutralizing antibodies directed against HGF, NRG1α, and NRG1β1 as well as combinations thereof (Fig. 5C). Here, HGF is linked to neoplasm.